Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and the tolerability of ADR-001 in Immunoglobulin A (IgA) Nephropathy patients. In addition, the investigators will evaluate the efficacy of ADR-001 for IgA Nephropathy patients.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04342325
Study type Interventional
Source Nagoya University
Contact
Status Completed
Phase Phase 1
Start date June 15, 2020
Completion date March 31, 2023